These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15780534)

  • 41. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors.
    Sorensen MB; Franks S; Robertson C; Pennell DJ; Collins P
    Clin Endocrinol (Oxf); 2006 Nov; 65(5):655-9. PubMed ID: 17054469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women.
    Talbott EO; Zborowski JV; Rager JR; Kip KE; Xu X; Orchard TJ
    J Womens Health (Larchmt); 2007 Mar; 16(2):191-7. PubMed ID: 17388735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited.
    Kurzrock R; Cohen PR
    Med Hypotheses; 2007; 68(3):480-3. PubMed ID: 17134841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stress in women: metabolic syndrome and polycystic ovary syndrome.
    Diamanti-Kandarakis E; Economou F
    Ann N Y Acad Sci; 2006 Nov; 1083():54-62. PubMed ID: 17148733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk?
    Daan NM; Louwers YV; Koster MP; Eijkemans MJ; de Rijke YB; Lentjes EW; Fauser BC; Laven JS
    Fertil Steril; 2014 Nov; 102(5):1444-1451.e3. PubMed ID: 25239303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome.
    Bik W; Baranowska-Bik A; Wolinska-Witort E; Chmielowska M; Martynska L; Baranowska B
    Gynecol Endocrinol; 2007 Jun; 23(6):325-31. PubMed ID: 17616856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome.
    Wiltgen D; Benedetto IG; Mastella LS; Spritzer PM
    Hum Reprod; 2009 Jul; 24(7):1726-31. PubMed ID: 19329517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Obese adolescent girls with polycystic ovary syndrome (PCOS) have more severe insulin resistance measured by HOMA-IR score than obese girls without PCOS.
    Sawathiparnich P; Weerakulwattana L; Santiprabhob J; Likitmaskul S
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S33-7. PubMed ID: 16856423
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia.
    Hahn S; Tan S; Elsenbruch S; Quadbeck B; Herrmann BL; Mann K; Janssen OE
    Horm Metab Res; 2005 Jul; 37(7):438-44. PubMed ID: 16034717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome.
    Yilmaz M; Bukan N; Ersoy R; Karakoç A; Yetkin I; Ayvaz G; Cakir N; Arslan M
    Hum Reprod; 2005 Sep; 20(9):2414-20. PubMed ID: 15890734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group.
    Farah L; Lazenby AJ; Boots LR; Azziz R
    J Reprod Med; 1999 Oct; 44(10):870-4. PubMed ID: 10554748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Not all women diagnosed with PCOS share the same cardiovascular risk profiles.
    Jovanovic VP; Carmina E; Lobo RA
    Fertil Steril; 2010 Aug; 94(3):826-32. PubMed ID: 19501355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of polycystic ovary syndrome and related factors between lesbian and heterosexual women.
    Smith HA; Markovic N; Matthews AK; Danielson ME; Kalro BN; Youk AO; Talbott EO
    Womens Health Issues; 2011; 21(3):191-8. PubMed ID: 21310628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome.
    Pasquali R; Patton L; Pagotto U; Gambineri A
    Minerva Ginecol; 2005 Feb; 57(1):79-85. PubMed ID: 15758867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS).
    Bhattacharya SM; Jha A
    Fertil Steril; 2010 Jun; 94(1):357-9. PubMed ID: 19896652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome.
    Cattrall FR; Healy DL
    Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):803-12. PubMed ID: 15380148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008.
    Okoroh EM; Hooper WC; Atrash HK; Yusuf HR; Boulet SL
    Am J Obstet Gynecol; 2012 Oct; 207(4):299.e1-7. PubMed ID: 22921097
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polycystic ovary syndrome: metabolic consequences and long-term management.
    Carmina E
    Scand J Clin Lab Invest Suppl; 2014; 244():23-6; discussion 26. PubMed ID: 25083889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.